patients

Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability DayMicroland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day

Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day

BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards ensuring care for patients with disease-related suffering, Microland Foundation,…

5 months ago
Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability DayMicroland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day

Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day

BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards ensuring care for patients with disease-related suffering, Microland Foundation,…

5 months ago
Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability DayMicroland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day

Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day

BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards ensuring care for patients with disease-related suffering, Microland Foundation,…

5 months ago
New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapyNew Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients…

5 months ago
A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter TechnologyA New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology

A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology

BTL, a leader in medical innovation, is proud to announce a major milestone: the successful treatment of the first patients…

5 months ago
A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter TechnologyA New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology

A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology

BTL, a leader in medical innovation, is proud to announce a major milestone: the successful treatment of the first patients…

5 months ago
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With InflammationRevascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy…

5 months ago
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson’s Disease PatientsSerina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson’s Disease Patients

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson’s Disease Patients

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced…

5 months ago
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…

5 months ago
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…

5 months ago
Show more Posts
Show previous Posts